A 56-week Phase IIIb/IV, Open-label, One-arm Extension Study to Assess the Efficacy and Safety of Brolucizumab 6 mg in a Treat-to-Control Regimen With Maximum Treatment Intervals up to 20 Weeks for the Treatment of Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Brolucizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms TALON Ext
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 21 Apr 2023 Status changed from active, no longer recruiting to completed.
- 06 Apr 2023 The trial has been completed in Belgium, according to European Clinical Trials Database record.
- 30 Mar 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.